The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lifetime exposure to a soluble TGF-β antagonist protects mice against metastasis without adverse side effects
Open accessAbstract
TGF-βs play diverse and complex roles in many biological processes. In tumorigenesis, they can function either as tumor suppressors or as pro-oncogenic factors, depending on the stage of the disease. We have developed transgenic mice expressing a TGF-β antagonist of the soluble type II TGF-β receptor:Fc fusion protein class, under the regulation of the mammary-selective MMTV-LTR promoter/enhancer. Biologically significant levels of antagonist were detectable in the serum and most tissues of this mouse line. The mice were resistant to the development of metastases at multiple organ sites when compared with wild-type controls, both in a tail vein metastasis assay using isogenic melanoma cells and in crosses with the MMTV-neu transgenic mouse model of metastatic breast cancer. Importantly, metastasis from endogenous mammary tumors was suppressed without any enhancement of primary tumorigenesis. Furthermore, aged transgenic mice did not exhibit the severe pathology characteristic of TGF-β null mice, despite lifetime exposure to the antagonist. The data suggest that in vivo the antagonist may selectively neutralize the undesirable TGF-β associated with metastasis, while sparing the regulatory roles of TGF-βs in normal tissues. Thus this soluble TGF-β antagonist has potential for long-term clinical use in the prevention of metastasis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The Fc-TβRII trap was also the basis for the development of a bi-specific trap that combines TGF-β binding by the TβRII ectodomains with a human PD-L1-blocking IgG1308,309,312.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [308]
In the citing paper
“Bifunctional fusion proteins that bind and block both TGF-β and CTLA-4 or PD-L1 have been generated, thus biochemically linking immune checkpoint inhibition with blocking TGF-β signaling308,309,365.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [308]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Manipulating the mouse embryo: A laboratory manual
Hogan, B. L. M., Costantini, F. D., & Lacy, E. (1986) · Cited by 4,460
Shull, M. M., Ormsby, I., Kier, A. B., Pawlowski, S., Diebold, R. J., Yin, M., Allen, R., Sidman, C., Proetzel, G., Calvin, D., et al. (1992) · Nature · doi:10.1038/359693a0 · Cited by 2,985
TGFβ Signaling in Growth Control, Cancer, and Heritable Disorders
Massagué, J., Blain, S. W., & Lo, R. S. (2000) · Cell · doi:10.1016/s0092-8674(00)00121-5 · Cited by 2,391
TGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
Kulkarni, A. B., Huh, C. G., Becker, D., Geiser, A., Lyght, M., Flanders, K. C., Roberts, A. B., Sporn, M. B., Ward, J. M., & Karlsson, S. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.770 · Cited by 1,967
Peptide Growth Factors and Their Receptors
Arai, K., Battey, J. F., Sporn, M. B., & Roberts, A. B. (1991) · Medical Entomology and Zoology · Cited by 1,225
Guy, C. T., Webster, M. A., Schaller, M. D., Parsons, T. J., Cardiff, R. D., & Muller, W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1
Border, W. A., Okuda, S., Languino, L. R., Sporn, M. B., & Ruoslahti, E. I. (1990) · Nature · doi:10.1038/346371a0 · Cited by 984
Border, W. A., Noble, N. A., Yamamoto, T., Harper, J. R., Yamaguchi, Y., Pierschbacher, M. D., & Ruoslahti, E. I. (1992) · Nature · doi:10.1038/360361a0 · Cited by 972
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L. R., Lees, E. M., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 964
Flagged first, then by citations
Research works printed but not linked: 4
- Gold, 1999, Crit Rev Oncog, 10, 303
- Engle, 1999, Cancer Res, 59, 3379
- Bottinger, 1997, Cancer Res, 57, 5564
- Dalal, 1993, Am J Pathol, 143, 381
Cited by
Sorted by citations
Items 401–405 of 405
Carcinoma-Associated Fibroblasts in Lung Cancer
Navab, R., Bandarchi, B., & Tsao, M. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0772-1_10
Vuorinen, K. (2008) · Työväentutkimus Vuosikirja
TGF-β at the Crossroads Between Inflammation, Suppression and Cancer
McCartney-Francis, N. L., & Wahl, S. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-293-9_34
Metadata
- Authors
- Yang, Y.-A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J. J., MacGregor, J., Patel, S. C., Khozin, S., Liu, Z.-Y., Green, J., Anver, M. R., Merlino, G., & Wakefield, L. M.
- Affiliations
- National Institutes of Health (US)
- Frederick National Laboratory for Cancer Research (US)
- Corresponding author
- Wakefield, Lalage M.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2002-06-15
- Volume
- 109
- Issue
- 12
- Pages
- 1607-1615
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC151015
- OpenAlex
- W2118916648
- Cited by
- 404
- References
- 50
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 1 · 2023: 4 · 2022: 3 · 2021: 8 · 2020: 9 · 2019: 5 · 2018: 5 · 2017: 6 · 2016: 8 · 2015: 9 · 2014: 17 · 2013: 19 · 2012: 30
- FWCI
- 12.90
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services
- National Institutes of Health (n01co12400-79-0-22, NO1-CO12400)
- National Cancer Institute (N01CO12400, N01-CO-012400, NO1‐CO‐12400)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- TGF-beta antagonists, Fc fusion protein, metastasis prevention, melanoma metastasis, MMTV-neu transgenic mice, breast cancer, transgenic mice
- MeSH terms
- Receptor, Transforming Growth Factor-beta Type II, Animals, Female, Genetic Vectors, Humans, Immunoglobulin G, Immunoglobulin Fc Fragments, Liver Neoplasms, Mammary Tumor Virus, Mouse, Melanoma, Experimental, Mice, Transgenic, Neoplasm Metastasis, Recombinant Fusion Proteins, Solubility, Tumor Cells, Cultured, Mammary Neoplasms, Animal, Transforming Growth Factor beta, Protein Serine-Threonine Kinases, Receptors, Transforming Growth Factor beta, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
